AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10453599
Drug: Massage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage treatment for recurrent respiratory tract infection; details on dosage and duration not specified.
Trial: 10453599
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (susceptible and healthy children); details on treatment not specified.
Trial: 29635505
Drug: Intact whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact whey protein (15 g)
Trial: 29635505
Drug: Hydrolyzed whey
RxNorm normalized name: amino acids/hydrolyzed collagen/hydrolyzed whey 15 gram-100 kcal/30 mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrolyzed whey protein (15 g)
Trial: 27569684
Drug: Both insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both insulin and saline infusion groups
Trial: 26586317
Drug: Chiropractic spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic spinal manipulative therapy (CSMT)
Trial: 26432128
Drug: Topical steroid-antibiotic
RxNorm normalized name: Betadine Antibiotic Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid-antibiotic alone
Trial: 18091666
Drug: Guided‐tissue regeneration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided‐tissue regeneration therapy (GTR) with scaling and root planing (SRP) and application of a bioresorbable membrane
Trial: 10690141
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg i.v.
Trial: 9500689
Drug: ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ursodeoxycholic acid (UDCA) 23-25 mg/kg/d
Trial: 2186630
Drug: ancrod 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ancrod 0.5 mu/kg in normal saline administered as a constant-rate intravenous infusion over 6 hours
Trial: 31968622
Drug: Brilliant Blue
RxNorm normalized name: Brilliant blue G
DrugBank: Brilliant blue G (DB15594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brilliant Blue G (BBG)
Trial: 25280823
Drug: Enhanced Treatment
RxNorm normalized name: Thera-M Enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Treatment as Usual (E-TAU)
Trial: 26063508
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 2.4 mg once every 2 months + 10 μg daily for residents, 3 mg once every 2 months for carers
Trial: 23860103
Drug: Active electrical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active electrical stimulation therapy
Trial: 20451663
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol 400 mg induction at weeks 0, 2, and 4; maintenance therapy randomized to every 2 weeks or every 4 weeks.
Trial: 20451663
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol 400 mg every 4 weeks maintenance therapy.
Trial: 20451663
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol 400 mg every 2 weeks maintenance therapy.
Trial: 20451663
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with certolizumab pegol.
Trial: 20451663
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with certolizumab pegol.
Trial: 16868453
Drug: fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluvastatin 80 mg/day
Trial: 24193155
Drug: Infliximab 10
RxNorm normalized name: infliximab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab 10 mg/kg
Trial: 23952962
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral local antifungal agents alone: gargle 2% sodium bicarbonate solution for 30 s, wait 10 min and then apply 2% nystatin paste)
Trial: 17397435
Drug: Oral desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral desmopressin (ddAVP)
Trial: 10836283
Drug: Venlafaxine 75
RxNorm normalized name: venlafaxine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 75 mg/day (days 1-4), 150 mg/day (days 5-10), 225 mg/day (days 11-42)
Trial: 10836283
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day (days 1-4), 40 mg/day (days 5-10), 60 mg/day (days 11-42)
Trial: 9096088
Drug: Technetium-99m labelled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technetium-99m labelled monoclonal antibody (MAb) 170H.82 at protein doses of 1, 2 and 4 mg
Trial: 9096088
Drug: Technetium-99m labelled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technetium-99m labelled monoclonal antibody (MAb) 170H.82 at 2 mg dose
Trial: 2938984
Drug: Nafarelin acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin acetate, D‐Nal(2)6‐GnRH, administered intranasally in a daily dose of 125 micrograms to 25 women.
Trial: 2938984
Drug: Nafarelin acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin acetate, D‐Nal(2)6‐GnRH, administered intranasally in a daily dose of 250 micrograms to 22 women.
Trial: 2938984
Drug: Nafarelin acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin acetate, D‐Nal(2)6‐GnRH, both doses (125 and 250 micrograms).
Trial: 25031187
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (GCBT)
Trial: 17565914
Drug: Ropivacaine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine administered pre‐incisionally and intraperitoneally (Group 1, n=14)
Trial: 1960557
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2
Trial: 7850540
Drug: Doxorubicin 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 90 mg/m2
Trial: 7850540
Drug: Doxorubicin 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 120 mg/m2
Trial: 27807281
Drug: Intra-arterial treatment
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial treatment in patients on prior antiplatelet treatment
Trial: 27807281
Drug: Intra-arterial treatment
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial treatment in patients not on prior antiplatelet treatment
Trial: 27807281
Drug: Successful reperfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful reperfusion in patients not on prior antiplatelet treatment
Trial: 27807281
Drug: Symptomatic intracranial
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRACRANIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic intracranial hemorrhage in patients on antiplatelet treatment
Trial: 27807281
Drug: Symptomatic intracranial
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRACRANIAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic intracranial hemorrhage in patients without antiplatelet treatment
Trial: 26194461
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus NP-delivered symptom management intervention (proactive telephone calls during the week after each of the first 2 chemotherapy visits)
Trial: 10859288
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg ASA daily
Trial: 10859288
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg ASA + 75 mg clopidogrel daily
Trial: 12772581
Drug: 0.5% chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% chitosan mouthrinse for 14 days, rinsing with 20 ml twice daily for 30 seconds
Trial: 10713862
Drug: Imipenem/cilastatin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (1,000 mg every 12 h)
Trial: 24521647
Drug: Meropenem (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (500 mg every 8 h)
Trial: 25466953
Drug: Tomato juice
RxNorm normalized name: TOMATO JUICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato juice (330 ml/d) for 20 days
Trial: 19339779
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of galantamine and memantine
Trial: 12199273
Drug: DHEA replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA replacement therapy
Trial: 2088195
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg) + Metronidazole (500 mg)
Trial: 1089875
Drug: Chenodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid, 750 mg per day
Trial: 1089875
Drug: Phenobarbital, 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital, 180 mg per day
Trial: 1089875
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chenodeoxycholic acid and phenobarbital
Trial: 31935028
Drug: Osocimab 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osocimab 0.3 mg/kg postoperative (n=107)
Trial: 31935028
Drug: Osocimab 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osocimab 0.6 mg/kg postoperative (n=65)
Trial: 31935028
Drug: Osocimab 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osocimab 1.2 mg/kg postoperative (n=108)
Trial: 31935028
Drug: Osocimab 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osocimab 1.8 mg/kg postoperative (n=106)
Trial: 31935028
Drug: Osocimab 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osocimab 0.3 mg/kg preoperative (n=109)
Trial: 31935028
Drug: Osocimab 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osocimab 1.8 mg/kg postoperative
Trial: 31935028
Drug: Osocimab 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osocimab 1.8 mg/kg preoperative
Trial: 29407718
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy (CBIT, Comprehensive Behavioral Intervention for Tics)
Trial: 29407718
Drug: Psychoeducation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation plus supportive therapy (PST)
Trial: 25451890
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of miglitol and sitagliptin (M+S)
Trial: 19841860
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL) 5 mg infusion
Trial: 22061864
Drug: Risedronate (RIS)
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Risedronate (RIS) 5 mg oral daily
Trial: 17456583
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg
Trial: 17456583
Drug: Oseltamivir 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 150 mg
Trial: 10866439
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg (in patients treated within 24 h of symptom onset)
Trial: 10866439
Drug: Oseltamivir 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 150 mg (in patients treated within 24 h of symptom onset)
Trial: 1586708
Drug: Lower-dose methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lower-dose methylprednisolone (LDM)
Trial: 26152562
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg, then 90 mg BID for 7-9 days)
Trial: 26152562
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg, then 75 mg QD for 7-9 days)
Trial: 24105694
Drug: PegIFNa2a at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNa2a at 90 μg/week
Trial: 24105694
Drug: Imatinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib at 400 mg with PegIFNa2a at 90 μg/week
Trial: 24105694
Drug: Imatinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib at 400 mg with PegIFNa2a at 45 μg/week
Trial: 24105694
Drug: Imatinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib at 400 mg with PegIFNa2a at 90 μg/week after dose amendment
Trial: 24105694
Drug: Imatinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib at 400 mg with PegIFNa2a at 45 μg/week after dose amendment
Trial: 15015441
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (including antisterone, tetracycline, and metronidazole)
Trial: 31435739
Drug: Rocuronium Maruishi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium Maruishi (0.9 mg/kg)
Trial: 31435739
Drug: Rocuronium MSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium MSD (0.9 mg/kg)
Trial: 19471183
Drug: Yi-Gan San
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yi-Gan San (YGS) at an average daily dosage of 6.7 +/- 2.5 g (range, 2.5-7.5 g)
Trial: 20540635
Drug: Probucol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (500 mg/day)
Trial: 7851034
Drug: Blood pump
RxNorm normalized name: Blood Pump Set 84"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pump flow rate of 200 cc/min
Trial: 7851034
Drug: Blood pump
RxNorm normalized name: Blood Pump Set 84"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pump flow rate of 500 cc/min
Trial: 7851034
Drug: Blood pump
RxNorm normalized name: Blood Pump Set 84"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pump flow rates beyond 300 cc/min
Trial: 3289598
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg plus nifedipine 20 mg each twice daily
Trial: 29947328
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care comprising scar management techniques (massage, moisturiser, silicone treatment, stretching)
Trial: 23457535
Drug: Continuous combination
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combination antiretroviral therapy (cART)
Trial: 18180976
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg monthly oral ibandronate
Trial: 15197428
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg intra-articular ketorolac
Trial: 15197428
Drug: 10 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cc intra-articular bupivacaine 0.25%
Trial: 15197428
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intra-articular morphine diluted in 10 cc saline
Trial: 15197428
Drug: 10 cc
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 cc saline
Trial: 2030189
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus standard inpatient treatment (pharmacotherapy and milieu management)
Trial: 29508046
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle training associated with behavioral therapy (GPFMT)
Trial: 21912128
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly supervised brushing with a self-applied gel containing 12,500 ppm fluoride
Trial: 21912128
Drug: Weekly supervised
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly supervised use of the gel
Trial: 16681480
Drug: Testosterone propionate
RxNorm normalized name: Testosterone Propionate
DrugBank: Testosterone propionate (DB01420)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone propionate (2 mg)
Trial: 11406907
Drug: Low-dose perindopril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose perindopril 2 mg plus indapamide 0.625 mg (P/I)
Trial: 11406907
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg (L50)
Trial: 9728841
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride solution (saline)
Trial: 7876403
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate (40 mg, 100 mg, 250 mg, 500 mg)
Trial: 7876403
Drug: Methylprednisolone suleptanate
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone suleptanate (40 mg, 100 mg, 250 mg, 500 mg)
Trial: 3555030
Drug: Ciprofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (750 mg twice daily)
Trial: 30924702
Drug: SPN-812 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-812 200 mg/day
Trial: 30358731
Drug: Intravaginal 0.50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal 0.50% DHEA (6.5 mg)
Trial: 24872223
Drug: Other variables
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other variables measured (urine N-telopeptide of type I collagen/creatinine ratio, Tanner score, serum parathyroid hormone, 25-hydroxyvitamin D, weight, height, body mass index)
Trial: 12809074
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU; 120 mg daily, for 3 months)
Trial: 27235849
Drug: Ibuprofen (1200mg/d)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (1200mg/d)
Trial: 20182022
Drug: Antihypertensive treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatments (specific subclasses: calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin-AT1-receptor-blockers)
Trial: 20182022
Drug: Antihypertensive treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatments (placebo-controlled)
Trial: 16096124
Drug: Preferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred treatment
Trial: 10071003
Drug: exercise therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exercise therapies
Trial: 7493304
Drug: All patients
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients who completed rIFN‐alpha 2b treatment
Trial: 7493304
Drug: All patients
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients post-therapy
Trial: 1973094
Drug: Combination low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination low sodium, low fat, high fibre diet
Trial: 25581612
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy or tumor necrosis factor plus methotrexate treatment
Trial: 2668757
Drug: Placebo vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal suppositories
Trial: 3698595
Drug: Meteneprost 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meteneprost 10 mg vaginal suppositories
Trial: 17919762
Drug: Twice-daily injections
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily injections of biphasic insulin aspart 30
Trial: 17919762
Drug: Three-times-daily injections
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three-times-daily injections of insulin aspart with or without NPH insulin (multiple daily injections)
Trial: 1958445
Drug: Tenoxicam (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam (40 mg daily for 2 days, then 20 mg daily for 8 days)
Trial: 31868632
Drug: Four cycles
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four cycles of R-CHOP plus two doses of rituximab